Literature DB >> 2486541

Hyperlipidemia of nephrosis: pathophysiologic role in progressive glomerular disease.

J R Diamond1.   

Abstract

During the past few years, the increasing speculation that the hyperlipidemia of nephrosis may be one of several pathogenic mechanisms involved in the progression of initial glomerular injury to glomerulosclerosis has generated many clinical and experimental investigations. This discussion reviews pertinent studies that address two major issues. First, the underlying pathophysiologic mechanisms involved in the development of the hyperlipidemia of nephrosis are explored. Second, this article examines recent studies that investigate how this secondary hyperlipidemia may further aggravate initial glomerular injury and contribute to a progressive glomerulopathy, primarily mediated through alterations in monocyte/macrophage function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2486541

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

Review 1.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

Review 2.  Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.

Authors:  G D'Amico
Journal:  Klin Wochenschr       Date:  1991-09-03

Review 3.  Hyperlipidemia in childhood nephrotic syndrome.

Authors:  M A Thabet; J R Salcedo; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

4.  Methionine restriction delays aging-related urogenital diseases in male Fischer 344 rats.

Authors:  Despina Komninou; Virginia L Malloy; Jay A Zimmerman; Raghu Sinha; John P Richie
Journal:  Geroscience       Date:  2019-11-14       Impact factor: 7.713

Review 5.  Role of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An Update.

Authors:  Cheng Wan; Hua Su; Chun Zhang
Journal:  Oxid Med Cell Longev       Date:  2016-08-15       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.